Collegium Pharmaceutical Settles Nucynta Patent Dispute
The company paid $17 million to resolve litigation and end a decade-long licensing agreement with Grünenthal GmbH.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Do you believe patent settlements between pharmaceutical companies negatively impact the cost of your medications?
Collegium Pharmaceutical has paid $17 million to Grünenthal GmbH to settle a patent infringement lawsuit regarding the authorized generic of Nucynta ER. The agreement officially terminates the licensing and royalty obligations between the two companies.
Why it matters
The settlement resolves pending litigation in federal court and discharges all remaining royalty obligations Collegium had under the original 2015 license. By finalizing this payment, the company secures full control over the relevant patents.
Collegium Pharmaceutical paid a $17 million settlement fee to resolve a patent lawsuit filed in February 2026. This ends a licensing arrangement first established in 2015 and later assumed by Collegium through an acquisition in 2020.
The players
Collegium Pharmaceutical
This is a specialty pharmaceutical company that focuses on developing and commercializing products for people living with pain.
Grünenthal GmbH
This is a research-based pharmaceutical company headquartered in Germany that specializes in pain management and related therapeutic areas.
The details
Grünenthal GmbH filed the patent infringement lawsuit against Collegium in a New Jersey federal court earlier this year. As part of the resolution, Grünenthal has filed a motion to dismiss the case and has assigned certain patents to Collegium.
Timeline
January 13, 2015: The original license agreement between the parties was established.
2020: Collegium Pharmaceutical acquired the rights to the Nucynta product.
February 2026: Grünenthal GmbH initiated the patent infringement lawsuit.
October 15, 2026: The settlement payment was made and the licensing agreement was terminated.
Market Landscape
This move reflects a broader trend of pharmaceutical companies opting to resolve protracted patent litigation through cash settlements and patent transfers. It allows Collegium to streamline its operations by eliminating recurring royalty obligations tied to its 2015 acquisition.
The resolution of this dispute clarifies the production and royalty status of the authorized generic of Nucynta ER. For patients and health providers, this shift simplifies the long-term supply and manufacturing framework for the medication.
The takeaway
This $17 million settlement provides a definitive conclusion to a multi-year legal conflict over drug patents. It highlights the strategic importance for firms to consolidate intellectual property rights following major corporate acquisitions.
Further reading
For more on industry legal developments, visit the Healthcare section.
Source note: This article includes information reported by TokenPost.
Live Poll
Do you believe patent settlements between pharmaceutical companies negatively impact the cost of your medications?
